Site Editor

Rebecca Olin, MD, MS

Advertisement
Advertisement

Tapan M. Kadia, MD, on Clinical Pearls: Treating AML With CPX-351 Plus Venetoclax

Posted: Thursday, January 7, 2021

Tapan M. Kadia, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical implications of treating acute myeloid leukemia with CPX-351 plus venetoclax—safety and efficacy data, cautions for clinicians prescribing this combination, and whether patients whose cancer responds may be able to undergo stem cell transplant.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.